Myeloproliferative Neoplasms (MPNs)
[Excluding CML] - Page 1

HEMMPD0036
Phase 2a/b of KRT-232 in PMF
Post-PV-MF, or Post- ET-MF
Pi: Gotlib
Sponsor: Karots Therapeutics

HEMMPD0046
Phase III Hepcidin Mimetic Ruxolitib (PTG-300) in Patients with Polycythemia Vera
Pi: Gotlib
Sponsor: Protagonist Therapeutics, Inc.

HEMMPD0035
Phase II Ruxolitinib in Idiopathic Hyper eosinophilic Syndrome & Primary Eosinophilic Disorders
Pi: Gotlib
Sponsor: Stanford University

Primary Myelofibrosis (PMF)

HEMMPD0041
Phase II/III INCB000928 +/- Ruxolitinib in Participants w/ Anemia Due to Myeloproliferative Disorders
Pi: Gotlib
Sponsor: Incyte Corporation

HEMMPD0047
Phase I Open-Label Multicenter Study of INCB033989 as Monotherapy or in Combo w/ Ruxolitinib in Myeloproliferative Neoplasms
Pi: Shomali
Sponsor: Incyte Corporation

HEMMPD0045
Hypereosinophilic Syndrome (HES)

KEY

| Pending | Open for Enrollment | Optional Path | Link | Trial Posting | Extension Study | Immunotherapy | Enrollment on Hold |

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu